Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics’ Chief Medical Officer, Adrian W. Quartel, reported several equity transactions. On January 29, 2026, he received 37,500 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 75,000 shares at an exercise price of $8.86.
The new RSUs will vest one third on January 29, 2027, with the remaining two thirds vesting in equal annual installments, subject to continued service. The stock option vests in four equal annual installments beginning on the first anniversary of the grant date, also subject to continued service.
On January 30, 2026, 11,333 RSUs vested and settled into common shares, and Quartel sold 4,533 shares at a weighted average price of $8.8321 under a Rule 10b5‑1(c) trading plan adopted on March 26, 2025, leaving 9,723 common shares held directly and 22,667 RSUs outstanding.
Zevra Therapeutics chief commercial officer Joshua Schafer reported multiple equity compensation events and a small share sale. On January 29, he received 37,500 restricted stock units and a stock option for 75,000 shares at $8.86 per share. On January 30, 11,333 RSUs vested and converted into common stock, and he sold 3,375 shares at a weighted average price of $8.8297 under a pre‑adopted Rule 10b5‑1(c) trading plan dated March 27, 2025. On January 31, a further 35,334 RSUs vested into common stock. The new RSU and option awards vest in multi‑year installments, contingent on his continued service.
Zevra Therapeutics President and CEO Neil F. McFarlane, who also serves as a director, reported several equity transactions. On February 2, 2026, he sold 91,000 shares of common stock at a weighted average price of $9.3783 per share under a Rule 10b5-1(c) trading plan adopted on March 21, 2025, leaving him with 364,350 common shares held directly.
On January 31, 2026, 233,334 restricted stock units (RSUs) vested and settled into the same number of common shares, increasing his directly held common stock to 455,350 shares before the subsequent sale and reducing his RSU balance to 233,333 units. Earlier, on January 29, 2026, he received equity awards of 125,000 RSUs and a 250,000-share stock option with a $8.86 exercise price, each subject to multi‑year vesting tied to continued service.
Form 144 discloses a planned sale of 105,625 shares of common stock, with an aggregate market value of $950,625.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ around 02/02/2026.
The securities were acquired on 01/31/2026 as restricted stock units from the issuer, with the same date listed for payment and the nature of payment marked as N/A. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
Zevra Therapeutics (symbol ZVRA) has a planned insider sale of shares under Rule 144. A holder intends to sell 4,750 shares of the company’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 42085.00 as of the notice.
The shares were acquired as restricted stock units from the issuer on 01/30/2026, with the same date shown for acquisition and payment. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information about Zevra’s current or prospective operations.
A shareholder of the issuer of ZVRA has filed a Rule 144 notice to sell 14,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on the NASDAQ, has an aggregate market value of $124,040.00.
The 14,000 shares were acquired from the issuer as restricted stock units dated 01/30/2026, with the same date listed for payment. The notice also reports 56,297,535 shares of the issuer’s common stock outstanding and confirms the seller represents having no undisclosed material adverse information.
A holder of ZVRA common stock filed a Rule 144 notice to sell 4,080 shares, with an aggregate market value of $36,148.80. The planned sale is through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/30/2026.
The shares come from restricted stock units acquired from the issuer on 01/30/2026 in the same amount of 4,080 units. The form notes that there are 56,297,535 ZVRA common shares outstanding at the time of this notice.
Zevra Therapeutics (symbol ZVRA) has a Form 144 filing indicating a planned insider sale of common stock. The notice covers 13,875 common shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $122,932.50. The planned sale is listed for 01/30/2026 on the NASDAQ market. The shares were acquired from the issuer on 01/30/2026 as restricted stock units, in a non-cash transaction described as “N/A” for the nature of payment. The filing also states that the person selling the securities represents they are not aware of any undisclosed material adverse information about the issuer’s operations.
ZVRA filed a notice for a planned insider stock sale under Rule 144. The person named in the filing intends to sell 4,533 shares of Zevra Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $40,162.38 on the NASDAQ.
The shares are being sold after acquisition as restricted stock units on 01/30/2026. Zevra Therapeutics had 56,297,535 common shares outstanding, which is a baseline figure for the company’s equity.
Zevra Therapeutics former CFO & Treasurer Clifton R. LaDuane reported equity transactions tied to his departure on December 31, 2025. On that date, 140,667 shares of common stock were issued at $0 upon vesting of previously granted restricted stock units and performance stock units. After this issuance, he held 192,028 common shares.
Also on December 31, 2025, 48,513 common shares were withheld at $8.96 per share to cover withholding taxes related to the vesting, leaving him with 143,515 common shares beneficially owned directly. The filing shows 86,667 and 34,000 restricted stock units and 20,000 performance stock units converting into common stock, with all such units fully vested and accelerated upon his departure, and no derivative units remaining.